

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

BB-1167-B

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)

09/720384INTERNATIONAL APPLICATION NO.
PCT/US99/15809INTERNATIONAL FILING DATE
13 JULY 1999 (13.07.99)PRIORITY DATE CLAIMED
14 JULY 1998 (14.07.98)

TITLE OF INVENTION

GENES ENCODING SULFATE ASSIMILATION PROTEINS

APPLICANT(S) FOR DO/EO/US

FALCO, Saverio Carl et al.


Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to bring national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application was filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau.
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371 (c) (2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409)
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included :

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☒ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail.
19. ☐ Other items or information:

17. General Power of Attorney**18. Express Mailing Label No.: EL031052192US**

APPLICATION NO. (IF KNOWN, SEE 37 CFR)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
09/720384		PCT/US99/15809		BB-1167-B	
20. The following fees are submitted				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)) :					
<input checked="" type="checkbox"/> Search Report has been prepared by the EPO or JPO				\$840.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482)				\$690.00	
<input type="checkbox"/> No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))				\$760.00	
<input type="checkbox"/> Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO				\$1000.00	
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4)				\$ 100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	11 - 20 =	0 x	\$18.00	\$0.00	
Independent Claims	3 - 3 =	0 x	\$80.00	\$0.00	
Multiple Dependent Claims (check if applicable)			<input type="checkbox"/>	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$0.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	\$0.00	
SUBTOTAL =				\$0.00	
Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input checked="" type="checkbox"/>	\$40.00	
TOTAL FEES ENCLOSED =				\$880.00	
				Amount to be : refunded	\$
				Charged	\$
<input type="checkbox"/> A check in the amount of _____ to cover the above fees enclosed.					
<input checked="" type="checkbox"/> Please charge my Deposit Account No. 04-1928 in the amount of \$880.00 to cover the above fees.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 04-1928 a duplicate copy of this sheet is enclosed.					
NOTE : Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
<div><div>RIZZO, THOMAS M. E. I. DU PONT DE NEMOURS AND COMPANY LEGAL PATENT RECORDS CENTER 1007 MARKET STREET WILMINGTON, DELAWARE 19898 UNITED STATES OF AMERICA</div><div> SIGNATURE RIZZO, THOMAS M. NAME 41,272 REGISTRATION NUMBER <i>December 14, 2000</i> DATE</div></div>					

TITLEGENES ENCODING SULFATE ASSIMILATION PROTEINS

This application claims the benefit of U.S. Provisional Application No. 60/092,833, filed July 14, 1998.

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding sulfate assimilation proteins in plants and seeds.

BACKGROUND OF THE INVENTION

Sulfate assimilation is the process by which environmental sulfur is fixed into organic sulfur for use in cellular metabolism. The two major end products of this process are the essential amino acids cysteine and methionine. These amino acids are limiting in food and feed; they cannot be synthesized by animals and thus must be acquired from plant sources. Increasing the level of these amino acids in feed products is thus of major economic value. Key to that process is increasing the level of organic sulfur available for cysteine and methionine biosynthesis.

Multiple enzymes are involved in sulfur assimilation. These include: High affinity sulfate transporter and low affinity sulfate transporter proteins which serve to transport sulfur from the outside environment across the cell membrane into the cell (Smith et al. (1995) *PNAS* 92(20):9373-9377). Once sulfur is in the cell sulfate adenylyltransferase (ATP sulfurylase) (Bolchia et al. (1999) *Plant Mol. Biol.* 39(3):527-537) catalyzes the first step in assimilation, converting the inorganic sulfur into an organic form, adenosine-5' phosphosulfate (APS). Next, several enzymes further modify organic sulfur for use in the biosynthesis of cysteine and methionine. For example, adenylylsulfate kinase (APS kinase), catalyzes the conversion of APS to the biosynthetic intermediate PAPS (3'-phospho-adenosine - 5' phosphosulfate) (Arz et al. (1994) *Biochim. Biophys. Acta* 1218(3):447-452). APS reductase (5' adenylyl phosphosulphate reductase) is utilized in an alternative pathway, resulting in an inorganic but cellularly bound (bound to a carrier), form of sulfur (sulfite) (Setya et al. (1996) *PNAS* 93(23):13383-13388). Sulfite reductase further reduces the sulfite, still attached to the carrier, to sulfide and serine O-acetyltransferase converts serine to O-acetylserine, which will serve as the backbone to which the sulfide will be transferred to from the carrier to form cysteine (Yonelcura-Sakakibara et al. (1998) *J. Biolchem.* 124(3):615-621 and Saito et al. (1995) *J. Biol. Chem.* 270(27):16321-16326).

As described, each of these enzymes is involved in sulfate assimilation and the pathway leading to cysteine biosynthesis, which in turn serves as an organic sulfur donor for multiple other pathways in the cell, including methionine biosynthesis. Together or singly these enzymes and the genes that encode them have utility in overcoming the sulfur limitations known to exist in crop plants. It may be possible to modulate the level of sulfur

containing compounds in the cell, including the nutritionally critical amino acids cysteine and methionine. Specifically, their overexpression using tissue specific promoters will remove the enzyme in question as a possible limiting step, thus increasing the potential flux through the pathway to the essential amino acids. This will allow the engineering of plant
5 tissues with increases levels of these amino acids, which now often must be added as supplements to animal feed.

SUMMARY OF THE INVENTION

The instant invention relates to isolated nucleic acid fragments encoding sulfate assimilation proteins. Specifically, this invention concerns an isolated nucleic acid fragment
10 encoding an APS kinase and an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding an APS kinase. In addition, this invention relates to a nucleic acid fragment that is complementary to the nucleic acid fragment encoding APS kinase. An additional embodiment of the instant invention pertains to a polypeptide encoding all or a substantial portion of an APS kinase.

15 In another embodiment, the instant invention relates to a chimeric gene encoding an APS kinase, or to a chimeric gene that comprises a nucleic acid fragment that is complementary to a nucleic acid fragment encoding an APS kinase, operably linked to suitable regulatory sequences, wherein expression of the chimeric gene results in production of levels of the encoded protein in a transformed host cell that is altered (i.e., increased or
20 decreased) from the level produced in an untransformed host cell.

In a further embodiment, the instant invention concerns a transformed host cell comprising in its genome a chimeric gene encoding an APS kinase, operably linked to suitable regulatory sequences. Expression of the chimeric gene results in production of altered levels of the encoded protein in the transformed host cell. The transformed host cell
25 can be of eukaryotic or prokaryotic origin, and include cells derived from higher plants and microorganisms. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

An additional embodiment of the instant invention concerns a method of altering the level of expression of an APS kinase in a transformed host cell comprising: a) transforming
30 a host cell with a chimeric gene comprising a nucleic acid fragment encoding an APS kinase; and b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of APS kinase in the transformed host cell.

An additional embodiment of the instant invention concerns a method for obtaining a
35 nucleic acid fragment encoding all or a substantial portion of an amino acid sequence encoding an APS kinase.

BRIEF DESCRIPTION OF THE
DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

5 Figure 1 shows a comparison of the amino acid sequences of the sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOs:13 and 14 respectively).

10 Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

15 TABLE 1
Sulfate Assimilation Proteins

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
APS kinase	cen3n.pk0088.b10	1	2
APS kinase	p0016.ctscj40rb	3	4
APS kinase	r10n.pk112.o11	5	6
APS kinase	sdp2c.pk013.a11	7	8
APS kinase	wr1.pk0101.e2	9	10
APS kinase	wre1n.pk0069.g5	11	12

20 The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Research* 13:3021-3030 (1985) and in the *Biochemical Journal* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

25 In the context of this disclosure, a number of terms shall be utilized. As used herein, a "nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. A nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65°C), with the nucleic acid fragments disclosed herein.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Preferred are those nucleic acid fragments whose nucleotide sequences encode amino acid sequences that are 80% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that

are 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are 95% identical to the amino acid sequences reported herein. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid.

Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic nucleic acid fragments” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. “Chemically synthesized”, as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.

“Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream

elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered: numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a double-stranded DNA that is complementary to and derived from mRNA. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by

reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

5 The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to
10 regulatory sequences in sense or antisense orientation.

 The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide.

15 "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

20 "Altered levels" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

 "Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and
25 propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

 A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a
30 nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*)
35 may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

“Transformation” refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as “transgenic” organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or “gene gun” transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter “Maniatis”).

Nucleic acid fragments encoding at least a portion of several sulfate assimilation proteins have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other APS kinase enzymes, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer

is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673; Loh et al. (1989) *Science* 243:217). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165).

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of APS kinase in those cells. This enzyme is involved in sulfate assimilation and the pathway leading to cysteine biosynthesis, which in turn serves as an organic sulfur donor for multiple other pathways in the cell, including methionine biosynthesis. This enzyme and the gene(s) that encodes the protein has utility in overcoming the sulfur limitations known to exist in crop plants. It may be possible to modulate the level of sulfur containing compounds in the cell, including the nutritionally critical amino acids cysteine and methionine. Specifically, their overexpression using tissue specific promoters will remove the enzyme in question as a possible limiting step, thus increasing the potential flux through the pathway to the essential amino acids. This will allow the engineering of plant tissues with increases levels of these amino acids, which now often must be added as supplements to animal feed.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding

sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric gene can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by altering the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences.

Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U. S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of

gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds, and is not an inherent part of the invention. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded sulfate assimilation protein. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

All or a substantial portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with

the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing
5 restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

10 The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4(1):37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of
15 individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).
20

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Research* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.
25

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 114(2):95-96),
30 polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nature Genetics* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a
35 nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the

region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149; Bensen et al. (1995) *Plant Cell* 7:75). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLE 1

Composition of cDNA Libraries: Isolation and Sequencing of cDNA Clones
cDNA libraries representing mRNAs from various corn, rice, soybean and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2
cDNA Libraries from Corn, Rice, Soybean and Wheat

Library	Tissue	Clone
cen3n	Corn (<i>Zea mays</i> L.) endosperm stage 3 (20 days after pollination)*	cen3n.pk0088.b10
p0016	Corn (<i>Zea mays</i> L.) pooled tassel shoots 0.1-1.4 cm	p0016.ctscj40rb
rl0n	Rice (<i>Oryza sativa</i> L.) 15 day leaf*	rl0n.pk112.o11
sdp2c	Soybean (<i>Glycine max</i> L.) developing pods 6-7 mm	sdp2c.pk013.a11
wrl	Wheat (<i>Triticum aestivum</i> L.) root; 7 day old seedling, light grown	wrl.pk0101.e2
wre1n	Wheat (<i>Triticum aestivum</i> L.) root; 7 day old etiolated seedling*	wre1n.pk0069.g5

*These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, incorporated herein by reference.

5

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP* XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP* XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

10

15

20

EXAMPLE 2

Identification of cDNA Clones

cDNA clones encoding sulfate assimilation proteins were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and

25

DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nature Genetics* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 3

Characterization of cDNA Clones Encoding APS Kinase

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to APS kinase from *Catharanthus roseus* (NCBI Identifier No. gi 2832300) and *Arabidopsis thaliana* (NCBI Identifier No. gi 1076283). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or contigs assembled from two or more ESTs ("Contig"):

TABLE 3

BLAST Results for Sequences Encoding Polypeptides Homologous to *Catharanthus roseus* and *Arabidopsis thaliana* APS Kinase

Clone	Status	BLAST pLog Score
cen3n.pk0088.b10	EST	88.30 (gi 2832300)
p0016.ctscj40rb	FIS	88.50 (gi 2832300)
r10n.pk112.o11	EST	52.30 (gi 1076283)
sdp2c.pk013.a11	FIS	97.30 (gi 2832300)
wr1.pk0101.e2	FIS	84.50 (gi 2832300)
wre1n.pk0069.g5	FIS	14.30 (gi 2832300)

Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOs:13 and 14 respectively). The data in Table 4 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 8, 10 and 12 and the *Catharanthus roseus* and *Arabidopsis thaliana* sequences (SEQ ID NOs:13 and 14).

TABLE 4

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Catharanthus roseus* and *Arabidopsis thaliana* APS Kinase

SEQ ID NO.	Percent Identity to
2	70% (gi 2832300)
4	52% (gi 2832300)
6	67% (gi 1076283)
8	56% (gi 2832300)
10	63% (gi 2832300)
12	63% (gi 2832300)

5

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASARGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of an APS kinase. These sequences represent the first corn, rice, soybean and wheat sequences encoding APS kinase.

15

EXAMPLE 4

Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb SalI-NcoI promoter fragment of the maize 27 kD zein gene and

20

25

30

a 0.96 kb SmaI-SalI fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be
5 screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

10 The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al.
15 (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

20 The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat*
25 gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm
30 in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant
35 removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 µL of ethanol. An aliquot (5 µL) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The

particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-
5 solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock
10 tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter
15 of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the
20 tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 5

Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription
25 terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the
30 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be
35 incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 5 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can maintained in 35 mL liquid media on a 10 rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70, U.S. Patent 15 No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 20 (from *E. coli*; Gritz et al.(1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

25 To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µl spermidine (0.1 M), and 50 µL CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can 30 be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally 35 bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 6

Expression of Chimeric Genes in Microbial Cells

The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio- β -galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 μ L of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One μ g of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

CLAIMS

What is claimed is:

1. An isolated nucleic acid fragment encoding an APS kinase comprising a member selected from the group consisting of:

5 (a) an isolated nucleic acid fragment encoding an amino acid sequence that is at least 80% identical to the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10 and 12

(b) an isolated nucleic acid fragment that is complementary to (a).

10 2. The isolated nucleic acid fragment of Claim 1 wherein nucleic acid fragment is a functional RNA.

3. The isolated nucleic acid fragment of Claim 1 wherein the nucleotide sequence of the fragment comprises the sequence set forth in a member selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9 and 11.

15 4. A chimeric gene comprising the nucleic acid fragment of Claim 1 operably linked to suitable regulatory sequences.

5. A transformed host cell comprising the chimeric gene of Claim 4.

6. An APS kinase polypeptide comprising all or a substantial portion of the amino acid sequence set forth in a member selected from the group consisting of SEQ ID NO:2, 4, 20 6, 8, 10 and 12.

7. A method of altering the level of expression of a sulfate assimilation protein in a host cell comprising:

(a) transforming a host cell with the chimeric gene of Claim 4; and
 25 (b) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene

wherein expression of the chimeric gene results in production of altered levels of a sulfate assimilation protein in the transformed host cell.

8. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a sulfate assimilation protein comprising:

30 (a) probing a cDNA or genomic library with the nucleic acid fragment of Claim 1;
 (b) identifying a DNA clone that hybridizes with the nucleic acid fragment of Claim 1;
 (c) isolating the DNA clone identified in step (b); and
 35 (d) sequencing the cDNA or genomic fragment that comprises the clone isolated in step (c)

wherein the sequenced nucleic acid fragment encodes all or a substantial portion of the amino acid sequence encoding a sulfate assimilation protein.

9. A method of obtaining a nucleic acid fragment encoding a substantial portion of an amino acid sequence encoding a sulfate assimilation protein comprising:

- 5
- (a) synthesizing an oligonucleotide primer corresponding to a portion of the sequence set forth in any of SEQ ID NOs:1, 3, 5, 7, 9, and 11; and
 - (b) amplifying a cDNA insert present in a cloning vector using the oligonucleotide primer of step (a) and a primer representing sequences of the cloning vector

wherein the amplified nucleic acid fragment encodes a substantial portion of an amino acid sequence encoding a sulfate assimilation protein.

- 10
- 10. The product of the method of Claim 8.
 - 11. The product of the method of Claim 9.

Figure 1

```

1
SEQ ID NO:2 ----- 60
SEQ ID NO:4 RPFHFINQTEPLVHTTQQPPSPAPGPASQ-GQRQGNLTLLSPTPTLAVILVNPQRAPPVLP
SEQ ID NO:6 -----
SEQ ID NO:8 -----ARATAKALRQPCYAGIFRNIEC-GPSPAAESLGFPKLRG-----INV
SEQ ID NO:10 -----TRADAGERMA-----G
SEQ ID NO:12 T-----
SEQ ID NO:13 -----MIGSVKRPVVSCVLPEFDFTSTGLGKKSSSVKLPVNFG-----AFG
SEQ ID NO:14 -----MIAAGAKSLL-----GLSMASPK-----G-----IFD

61
SEQ ID NO:2 SAA-----AAVAGISSSSSA----- 120
SEQ ID NO:4 GLTPSDAPLPALVIHGLTPRSSHSSAGLASDSGRREGEGRGARTHCHRGIGRWVRRRRRN
SEQ ID NO:6 -----
SEQ ID NO:8 TGLHCGRRGLVLVLRASKPIRAKEN--ASVSASLID-DWFKPITAKED-----S
SEQ ID NO:10 SEA-----VPVVAVAAGKQP-----VNG-----
SEQ ID NO:12 -----
SEQ ID NO:13 SGG--GEVKLGFLAPIKATEGSKTSS--FQVNGKVDNFRHLQPSDCNSN-----S
SEQ ID NO:14 SNSMSNSRSVVVVRACVSMDSQTLS--HNKNGSIPEVKSI-----

121
SEQ ID NO:2 -----LVTSTVGKSTNWLWHECAIGQKERQGLLNQKGCVVWITGLSGSGK 180
SEQ ID NO:4 GAAPGEAPHSPVKEKPVMSNIGKSTNWLWHNCLIGQSDRQKLLGQKGCVVWITGLSGSGK
SEQ ID NO:6 -----SIVPKASNI FWHDCAVGQADRQKLLKQKGCVVWITGLSGSGK
SEQ ID NO:8 NAE-DRTSSFSGKNLTQMSNVGNSTNIMWHDCPIQKQDRQQLLQQQGCVIWLTLGLSGSGK
SEQ ID NO:10 -----SAMAGIDKLVTSTVGKSTNVLWHDCPIGQFERQELLNQKGCVVWITGLSGSGK
SEQ ID NO:12 -----
SEQ ID NO:13 DSSLNNCNGFPGKKILQTTTVGNSTNWLWHKCAVEKSERQEPLQQRGCVIWLTLGLSGSGK
SEQ ID NO:14 -----NGHTGQKQGPLSTVGNSTNIKWHECSVEKVDRQLLDQKGCVIWVTLGLSGSGK

181
SEQ ID NO:2 STLACALSRELHGRGHLTYVLDGDNLRHGLNRDLSFGAEDRAENIRRVGEVAKLFADAGL 240
SEQ ID NO:4 STLACALSRELHCRGHLTYVLDGDNLRHGLNRDLSFKAEDRAENIRRVGEVAKLFADAGV
SEQ ID NO:6 STLACTLDRELHTRGKLSYVLDGDNLRHGLNKDLGFAEDRAENIRKVGGEVAKLFXDASL
SEQ ID NO:8 STIACALSQSLHSGKLSYILDGDNIRHGLNQDLSFRAEDRSNIRRIGEVAKLFDAGV
SEQ ID NO:10 STLACALSRELHSGHLTYILDGDNLRHGLNRDLCFEAKDRAENIRRVGEVAKLFADAGL
SEQ ID NO:12 -----
SEQ ID NO:13 STLACALSRLHAKGKLTYYLDGDNVRHGLNSDLSFKAEDRAENIRRIGEVAKLFDAGV
SEQ ID NO:14 STLACALNQMLYQKGKLCYILDGDNVRHGLNRDLSFKAEDRAENIRRVGEVAKLFADAGI

241
SEQ ID NO:2 VCIASLISPYRSRDSACRDLLPKHSFIEVFLDVPLQVCEARDPKGLYKLARAGKIKGFTG 300
SEQ ID NO:4 ICIASLISPYRRDRDACRALLPHSNFIEVFIDLPLKICEARDPKGLYKLARTGKIKGFTG
SEQ ID NO:6 VCIASFKSPYKRER-----
SEQ ID NO:8 ICITSLISPYQKDRDACRALLSKGDFIEVFIDVPLHVCEARDPKGLYKLARAGKIKGFTG
SEQ ID NO:10 ICIASLISPYRSERSACRKLHNSTFIEVFLNVPLEVCEARDPKGLYKLARAGKIKGFTG
SEQ ID NO:12 -----RLARTGKIKGFTG
SEQ ID NO:13 ICIASLISPYRKPPDACRSLLEPGDFIEVFMDVPLKVCEARDPKGLYKLARAGKIKGFTG
SEQ ID NO:14 ICIASLISPYRTDRDACRSLLEPGDFIEVFMDVPLSVCEARDPKGLYKLARAGKIKGFTG

```

Figure 1 (cont'd.)

	301	344
SEQ ID NO:2	IDDPYEPPSDCEIVIQCKVGDCPSPESMAGHVVSYLETNGFLQD	
SEQ ID NO:4	IDDPYEPPINGEIVIKMKDEECPSPKAMAKQVLCYLEENGYLQA	
SEQ ID NO:6	-----ES	
SEQ ID NO:8	IDDPYEPPCSCEIVLQQKGS DCKSPSDMAEEVISYLEENGYLRA	
SEQ ID NO:10	IDDPYEAPSDCEIVIQCKAGDCATPKSMADQVVSYLEANEFLQE	
SEQ ID NO:12	VDDPYESPVNSEIVIKMEGGECPSPKAMAQQVLSYLEKNGYLQA	
SEQ ID NO:13	IDDPYEPLKSEIVLHQKLGMCDSPCDLADIVISYLEENGYLKA	
SEQ ID NO:14	IDDPYEPLNCEISLGREGG--TSPIEMA EKVVGYLDNKGYLQA	

SEQUENCE LISTING

<110> E. I. du Pont de Nemours and Company
 <120> Genes Encoding Sulfate Assimilation Proteins
 <130> BB-1167-B
 <140>
 <141>
 <150> 60/092,833
 <151> July 14, 1998
 <160> 14
 <170> Microsoft Office 97
 <210> 1
 <211> 890
 <212> DNA
 <213> Zea mays

<400> 1
 ggtcagcggc ggcgccgctc gcagggatca gcagcagcag cagcgcgctg gtgacctcga 60
 ccgtcgggaa atcgacgaac atcctgtggc atgagtgcgc catcgggcag aaggagcgac 120
 agggctctgct gaaccagaag ggctgcgtcg tgtggatcac tggcctaagc ggttcaggga 180
 aaagcacgct cgcgtgcgcg ctgagccgcg agctgcacgg cagaggccac ctcacgtacg 240
 tcctcgacgg cgacaacctc aggcacgggc tgaacaggga cctcagcttc ggagcagagg 300
 accgcgccga gaacatccgc agagtgggg aagtagcgaa gctgttcgcc gacgtggcc 360
 tcgtctgcat cgccagcctc atatcgccct acagaagcga ccgaagcgcg tgtcgcgatc 420
 tgctgccccaa gcactcgttt atcgaggtgt tcctggacgt gccgcttcaa gtgtgcgaag 480
 ccagggaccc caaaggcctc tacaagctcg cacgcgccgg caaaatcaaa ggggttcaccg 540
 gcatcgacga tccttacgaa ccgccgtcgg actgtgagat agtgatccag tgtaaagtcg 600
 gcgactgccc ttgcctgaa tcgatggctg gtcacgttgt gtcgtacctt gagacgaatg 660
 gtttcctcca ggactagaca tggaaatgcga tcgatgcgtc tgatgtgtat atatgtagca 720
 gcagccggag cggcattgcc aaggctgtgt aatctcatgg ctgtctttct ctttaagacc 780
 aaaacaaaaca agagatggca gtgtaaaaag gaaaaaaaaa actgcgtctg acagagtcgc 840
 tgaatcaacc atgcttctga taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 890

<210> 2
 <211> 224
 <212> PRT
 <213> Zea mays

<400> 2
 Ser Ala Ala Ala Ala Val Ala Gly Ile Ser Ser Ser Ser Ser Ala Leu
 1 5 10 15
 Val Thr Ser Thr Val Gly Lys Ser Thr Asn Ile Leu Trp His Glu Cys
 20 25 30
 Ala Ile Gly Gln Lys Glu Arg Gln Gly Leu Leu Asn Gln Lys Gly Cys
 35 40 45
 Val Val Trp Ile Thr Gly Leu Ser Gly Ser Gly Lys Ser Thr Leu Ala
 50 55 60
 Cys Ala Leu Ser Arg Glu Leu His Gly Arg Gly His Leu Thr Tyr Val
 65 70 75 80

Leu Asp Gly Asp Asn Leu Arg His Gly Leu Asn Arg Asp Leu Ser Phe
 85 90 95
 Gly Ala Glu Asp Arg Ala Glu Asn Ile Arg Arg Val Gly Glu Val Ala
 100 105 110
 Lys Leu Phe Ala Asp Ala Gly Leu Val Cys Ile Ala Ser Leu Ile Ser
 115 120 125
 Pro Tyr Arg Ser Asp Arg Ser Ala Cys Arg Asp Leu Leu Pro Lys His
 130 135 140
 Ser Phe Ile Glu Val Phe Leu Asp Val Pro Leu Gln Val Cys Glu Ala
 145 150 155 160
 Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala Arg Ala Gly Lys Ile Lys
 165 170 175
 Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu Pro Pro Ser Asp Cys Glu
 180 185 190
 Ile Val Ile Gln Cys Lys Val Gly Asp Cys Pro Ser Pro Glu Ser Met
 195 200 205
 Ala Gly His Val Val Ser Tyr Leu Glu Thr Asn Gly Phe Leu Gln Asp
 210 215 220

<210> 3
 <211> 1217
 <212> DNA
 <213> Zea mays

<400> 3
 ggcgtccggttt cattttcatca atcaaacaga acctctgggtc acacacacgc agcaaccacc 60
 gagcccagcg cccggcccag ccagccaggg ccaacggcaa ggcaacaccc tcttcagccc 120
 gacgccgacg ctgcgcgtca tcttcgtaaa tccacagcgc gcgcctcccg tcttcccagg 180
 cctcacccct agcgatgcgc cactcccggc gctcgtgata catggcctca ctccccgttc 240
 ctcacactct tccgcgggtc tcgccagtga tagtgggcgc cgcgaggggg agggccgcgg 300
 tgcgcgtacg cactgccacc gcggcattgg gcggtgggtg cggcggcggc ggcggaatgg 360
 agcagcgcgc ggggaggccc cgcacagccc agtgaaggag aagcctgtaa tgtcgaacat 420
 tgggaaatcg actaatattt tatggcacia ttgcttgatt ggacaatctg atagacagaa 480
 attgctggga caaaaaggct gtgtcgatg gataacagga ctcatgggtt cagggaaaag 540
 tactcttgca tgtgactga gtcgtagatt gcattgcaga ggccacctca cgtatgtact 600
 tgatggtgac aacctcagac atggcctaaa tagagattta agctttaagg cagaagaccg 660
 tgcagaaaat atacgaagag ttggtgaagt ggcaaagctt tttgctgatg ctggtgtcat 720
 atgcattgct agcttgatat ctccatacag gagagatcgt gatgcatgcc gtgctctact 780
 tccacattct aactttattg aagtatttat tgatttgccc ctaaaaattt gtgaagctcg 840
 tgatcctaaa ggcctataca agcttgacag tacaggaaag attaaagggt tcatggaat 900
 tgatgatcca tacgaaccac caattaatgg tgagatagta attaatga aagatgagga 960
 atgcccttca cccaaagcaa tggccaagca agttctatgc taccttgaag aaaacggata 1020
 tttgcaagct tagtatatgt attttgagaa gattgatctg attcttgtgt gtccattact 1080
 tgtggacaca ataagatctg ttgttggtca catgaataaa aggcataaac atgtaggaag 1140
 taacagaagg tacggttcat tcagaaacgg atatggattc attcgtttta aaaaaaaaaa 1200
 aaaaaaaaaa aaaaaaa 1217

<210> 4
 <211> 343
 <212> PRT
 <213> Zea mays

<400> 4
 Arg Pro Phe His Phe Ile Asn Gln Thr Glu Pro Leu Val Thr His Thr
 1 5 10 15
 Gln Gln Pro Pro Ser Pro Ala Pro Gly Pro Ala Ser Gln Gly Gln Arg
 20 25 30
 Gln Gly Asn Thr Leu Leu Ser Pro Thr Pro Thr Leu Ala Val Ile Leu
 35 40 45
 Val Asn Pro Gln Arg Ala Pro Pro Val Leu Pro Gly Leu Thr Pro Ser
 50 55 60
 Asp Ala Pro Leu Pro Ala Leu Val Ile His Gly Leu Thr Pro Arg Ser
 65 70 75 80
 Ser His Ser Ser Ala Gly Leu Ala Ser Asp Ser Gly Arg Arg Glu Gly
 85 90 95
 Glu Gly Arg Gly Ala Arg Thr His Cys His Arg Gly Ile Gly Arg Trp
 100 105 110
 Val Arg Arg Arg Arg Arg Asn Gly Ala Ala Pro Gly Glu Ala Pro His
 115 120 125
 Ser Pro Val Lys Glu Lys Pro Val Met Ser Asn Ile Gly Lys Ser Thr
 130 135 140
 Asn Ile Leu Trp His Asn Cys Leu Ile Gly Gln Ser Asp Arg Gln Lys
 145 150 155 160
 Leu Leu Gly Gln Lys Gly Cys Val Val Trp Ile Thr Gly Leu Ser Gly
 165 170 175
 Ser Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Glu Leu His Cys
 180 185 190
 Arg Gly His Leu Thr Tyr Val Leu Asp Gly Asp Asn Leu Arg His Gly
 195 200 205
 Leu Asn Arg Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn Ile
 210 215 220
 Arg Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val Ile
 225 230 235 240
 Cys Ile Ala Ser Leu Ile Ser Pro Tyr Arg Arg Asp Arg Asp Ala Cys
 245 250 255
 Arg Ala Leu Leu Pro His Ser Asn Phe Ile Glu Val Phe Ile Asp Leu
 260 265 270
 Pro Leu Lys Ile Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu
 275 280 285
 Ala Arg Thr Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr
 290 295 300

Glu Pro Pro Ile Asn Gly Glu Ile Val Ile Lys Met Lys Asp Glu Glu
305 310 315 320

Cys Pro Ser Pro Lys Ala Met Ala Lys Gln Val Leu Cys Tyr Leu Glu
325 330 335

Glu Asn Gly Tyr Leu Gln Ala
340

<210> 5
<211> 431
<212> DNA
<213> Oryza sativa

<220>
<221> unsure
<222> (48)

<220>
<221> unsure
<222> (346)

<220>
<221> unsure
<222> (431)

<400> 5
cttacacaga gatcaggtag aacagtgggc gagaacaaag ttttgcanat gtcattcaatt 60
gtgccgaagg cgtccaatat cttctggcat gattgtgcag ttggccaggc tgatcggcag 120
aagctactga agcagaaaagg ttgcgttggt tggatcacag gacttagtgg ttcaggtaaa 180
agtaccctgg catgcacatt agatcgagag ctccatacaa gagggaagct ttcttatggt 240
cttgatggtg ataatttaag acatggtttg aacaaggatc ttggctttaa ggcggaagac 300
cgtgctgaaa atatacgcaa agttggtgag gtagcaaaagc tattcncaga tgcaagccta 360
gtatgcattg caagtttcaa atctccctat aagagagAAC gtgagtcctg gccctgcaat 420
attgtcaaat n 431

<210> 6
<211> 118
<212> PRT
<213> Oryza sativa

<220>
<221> UNSURE
<222> (98)

<400> 6
Ser Ile Val Pro Lys Ala Ser Asn Ile Phe Trp His Asp Cys Ala Val
1 5 10 15
Gly Gln Ala Asp Arg Gln Lys Leu Leu Lys Gln Lys Gly Cys Val Val
20 25 30
Trp Ile Thr Gly Leu Ser Gly Ser Gly Lys Ser Thr Leu Ala Cys Thr
35 40 45
Leu Asp Arg Glu Leu His Thr Arg Gly Lys Leu Ser Tyr Val Leu Asp
50 55 60
Gly Asp Asn Leu Arg His Gly Leu Asn Lys Asp Leu Gly Phe Lys Ala
65 70 75 80

Glu Asp Arg Ala Glu Asn Ile Arg Lys Val Gly Glu Val Ala Lys Leu
85 90 95

Phe Xaa Asp Ala Ser Leu Val Cys Ile Ala Ser Phe Lys Ser Pro Tyr
100 105 110

Lys Arg Glu Arg Glu Ser
115

<210> 7
<211> 936
<212> DNA
<213> Glycine max

<400> 7
gcacgagcca ccgcgaaggc tctgcgacag ccctgctacg ccggaatctt tcgcaacatc 60
gaatgcggcc cgtcgccggc ggcgagtcg ctagggtttc cgaagctccg cggaatcaac 120
gtcactggat tgcactgcgg ccgcgaggc ctcgctcctg tcctccgtgc aaaatcaaag 180
ccgattaggg cgaaggagaa cgcaagcgta agtgcttctc tgatcgatga ctggttcaag 240
ccaattacgg cgaaggagga ttctaacgca gaggaccgta catcttcggt ttctggtaaa 300
aatctcacc cagatgtcaaa tgttggaac tcgacaaaca ttatgtggca tgactgtcca 360
attcagaaac aagatagaca gcagctgctt cagcaacaag gctgtgttat atggctaact 420
ggcctcagcg gacagagaaa aagcactatt gcatgtgctc tgagtcaaag cttgcactcc 480
aaaggaaaac tgtcttacct ccttgatggt gacaatattc ggcatggtct aaaccaggat 540
cttagtttta gagcagaaga tegtctgaa aacattagaa ggattggtga ggtggcaaaa 600
ctctttgcag atgctggtgt tatttgcac actagtttaa tatcaccata ccaaaggat 660
agagatgcat gcagagcact actttcaaaa ggagatttta ttgaggtttt catagatgtt 720
ccactacatg tgtgtgaagc tagggaccca aaggactct acaagcttgc tcgagctgga 780
aagatcaaag gtttactagg tatagatgat ccatatgaac caccgtgtag ttgtgagata 840
gtattacaac agaaaggaag tgactgtaag tctcccagtg atatggctga agaagtata 900
tcctacttgg aggagaacgg atacctgcgg gcttga 936

<210> 8
<211> 311
<212> PRT
<213> Glycine max

<400> 8
Ala Arg Ala Thr Ala Lys Ala Leu Arg Gln Pro Cys Tyr Ala Gly Ile
1 5 10 15
Phe Arg Asn Ile Glu Cys Gly Pro Ser Pro Ala Ala Glu Ser Leu Gly
20 25 30
Phe Pro Lys Leu Arg Gly Ile Asn Val Thr Gly Leu His Cys Gly Arg
35 40 45
Arg Gly Leu Val Leu Val Leu Arg Ala Lys Ser Lys Pro Ile Arg Ala
50 55 60
Lys Glu Asn Ala Ser Val Ser Ala Ser Leu Ile Asp Asp Trp Phe Lys
65 70 75 80
Pro Ile Thr Ala Lys Glu Asp Ser Asn Ala Glu Asp Arg Thr Ser Ser
85 90 95
Phe Ser Gly Lys Asn Leu Thr Gln Met Ser Asn Val Gly Asn Ser Thr
100 105 110

Asn Ile Met Trp His Asp Cys Pro Ile Gln Lys Gln Asp Arg Gln Gln
 115 120 125
 Leu Leu Gln Gln Gln Gly Cys Val Ile Trp Leu Thr Gly Leu Ser Gly
 130 135 140
 Ser Gly Lys Ser Thr Ile Ala Cys Ala Leu Ser Gln Ser Leu His Ser
 145 150 155 160
 Lys Gly Lys Leu Ser Tyr Ile Leu Asp Gly Asp Asn Ile Arg His Gly
 165 170 175
 Leu Asn Gln Asp Leu Ser Phe Arg Ala Glu Asp Arg Ser Glu Asn Ile
 180 185 190
 Arg Arg Ile Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val Ile
 195 200 205
 Cys Ile Thr Ser Leu Ile Ser Pro Tyr Gln Lys Asp Arg Asp Ala Cys
 210 215 220
 Arg Ala Leu Leu Ser Lys Gly Asp Phe Ile Glu Val Phe Ile Asp Val
 225 230 235 240
 Pro Leu His Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu
 245 250 255
 Ala Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr
 260 265 270
 Glu Pro Pro Cys Ser Cys Glu Ile Val Leu Gln Gln Lys Gly Ser Asp
 275 280 285
 Cys Lys Ser Pro Ser Asp Met Ala Glu Glu Val Ile Ser Tyr Leu Glu
 290 295 300
 Glu Asn Gly Tyr Leu Arg Ala
 305 310

<210> 9
 <211> 928
 <212> DNA
 <213> Triticum aestivum

<400> 9
 gcacgagggc ggacgcaggg gagaggatgg cgggggtcaga agccgtgccg gtggtggctg 60
 tggctgccgg gaagcagccc gtcaatggat cagccatggc aggtatcgac aagcttgtga 120
 cctcaactgt tgggaaatcg acaaacgttc tttggcatga ctgtccaata ggtcagtttg 180
 agaggcagga actgctaaat cagaagggtt gtgttgtgtg gataacaggg ttaagtgggt 240
 cagggaaaag cacactagca tgcgcgctaa gtcgcgagct gcactccaga ggtcatctga 300
 cctacattct agacggtgac aatctaaggc atgggttaaa ccgagacctc tgtttcgaag 360
 caaaggaccg tgctgaaaat atacgcagag taggagaagt agcaaagctg tttgcagatg 420
 ctggtctgat ctgcattgct agcttgatat caccctacag aagtgaacgc agcgcttgcc 480
 gcaaattact gcacaattct acattcatcg aggtgttttt gaatgtccca ctggaagttt 540
 gtgaagctag ggatccaaaa ggcttgtaca agcttgcccg tgcaggaaaa atcaaagggt 600
 ttactggaat tgatgatcct tatgaagcac cttctgactg cgagatagtg atacagtga 660
 aagctggtga ctgcgccacg cctaaatoga tggctgatca agttgtgtca tatcttgaag 720
 caaatgagtt cttacaggaa tagagacgta tgctatggat gaaaaaacat tctgaaattg 780
 gatcgccaag ggatgtgaaa tatgaggtag tatttatgtc tagaaagagt gatgatagta 840
 tgagaacata tatattgaca taaagatcga atctgtacat cattataata aattgaaatg 900

ttttgacgca aaaaaaaaaa aaaaaaaaaa

928

<210> 10

<211> 246

<212> PRT

<213> Triticum aestivum

<400> 10

Thr Arg Ala Asp Ala Gly Glu Arg Met Ala Gly Ser Glu Ala Val Pro
1 5 10 15

Val Val Ala Val Ala Ala Gly Lys Gln Pro Val Asn Gly Ser Ala Met
20 25 30

Ala Gly Ile Asp Lys Leu Val Thr Ser Thr Val Gly Lys Ser Thr Asn
35 40 45

Val Leu Trp His Asp Cys Pro Ile Gly Gln Phe Glu Arg Gln Glu Leu
50 55 60

Leu Asn Gln Lys Gly Cys Val Val Trp Ile Thr Gly Leu Ser Gly Ser
65 70 75 80

Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Glu Leu His Ser Arg
85 90 95

Gly His Leu Thr Tyr Ile Leu Asp Gly Asp Asn Leu Arg His Gly Leu
100 105 110

Asn Arg Asp Leu Cys Phe Glu Ala Lys Asp Arg Ala Glu Asn Ile Arg
115 120 125

Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Leu Ile Cys
130 135 140

Ile Ala Ser Leu Ile Ser Pro Tyr Arg Ser Glu Arg Ser Ala Cys Arg
145 150 155 160

Lys Leu Leu His Asn Ser Thr Phe Ile Glu Val Phe Leu Asn Val Pro
165 170 175

Leu Glu Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala
180 185 190

Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu
195 200 205

Ala Pro Ser Asp Cys Glu Ile Val Ile Gln Cys Lys Ala Gly Asp Cys
210 215 220

Ala Thr Pro Lys Ser Met Ala Asp Gln Val Val Ser Tyr Leu Glu Ala
225 230 235 240

Asn Glu Phe Leu Gln Glu
245

<210> 11

<211> 521

<212> DNA

<213> Triticum aestivum

```

<400> 11
gcacgaggct tgcacgcaca ggaaagatta aagggttcac cggagttgat gatccatacg 60
aatcaccagt gaatagttag atagtaatta agatggaagg tggggaatgc ccttcaccga 120
aggcaatggc ccagcaagtt ctgtcctacc ttgagaagaa cggatatttg caggcttagc 180
atatatatac tccagatcca gaagattgaa cttattcttc tgtgtccata actcatggac 240
acaggcatga tccatttggg cgcacccgga ataaaaggcg ctgttattga agcaacaagc 300
tgcctttttc acgggggaaag ggacgcagat cgatgatcag tttgattggt cggcattgct 360
cctctcgcg cgtgttgctg attttagctg tagtctatac ttgctcattt cggctgaaat 420
ggtgtgctgt gctgtgctgt gtttatttgt tggtaatgta tgatttgatt gtgggtgtca 480
aaagtacgaa tgaataaatc gtgcttgctg tttcaaaaaa a 521

```

```

<210> 12
<211> 58
<212> PRT
<213> Triticum aestivum

```

```

<400> 12
Thr Arg Leu Ala Arg Thr Gly Lys Ile Lys Gly Phe Thr Gly Val Asp
  1             5             10             15

Asp Pro Tyr Glu Ser Pro Val Asn Ser Glu Ile Val Ile Lys Met Glu
          20             25             30

Gly Gly Glu Cys Pro Ser Pro Lys Ala Met Ala Gln Gln Val Leu Ser
      35             40             45

Tyr Leu Glu Lys Asn Gly Tyr Leu Gln Ala
  50             55

```

```

<210> 13
<211> 312
<212> PRT
<213> Catharanthus roseus

```

```

<400> 13
Met Ile Gly Ser Val Lys Arg Pro Val Val Ser Cys Val Leu Pro Glu
  1             5             10             15

Phe Asp Phe Thr Glu Ser Thr Gly Leu Gly Lys Lys Ser Ser Ser Val
      20             25             30

Lys Leu Pro Val Asn Phe Gly Ala Phe Gly Ser Gly Gly Gly Glu Val
      35             40             45

Lys Leu Gly Phe Leu Ala Pro Ile Lys Ala Thr Glu Gly Ser Lys Thr
  50             55             60

Ser Ser Phe Gln Val Asn Gly Lys Val Asp Asn Phe Arg His Leu Gln
  65             70             75             80

Pro Ser Asp Cys Asn Ser Asn Ser Asp Ser Ser Leu Asn Asn Cys Asn
          85             90             95

Gly Phe Pro Gly Lys Lys Ile Leu Gln Thr Thr Thr Val Gly Asn Ser
      100             105             110

Thr Asn Ile Leu Trp His Lys Cys Ala Val Glu Lys Ser Glu Arg Gln
  115             120             125

```

Glu Pro Leu Gln Gln Arg Gly Cys Val Ile Trp Ile Thr Gly Leu Ser
 130 135 140
 Gly Ser Gly Lys Ser Thr Leu Ala Cys Ala Leu Ser Arg Gly Leu His
 145 150 155 160
 Ala Lys Gly Lys Leu Thr Tyr Ile Leu Asp Gly Asp Asn Val Arg His
 165 170 175
 Gly Leu Asn Ser Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn
 180 185 190
 Ile Arg Arg Ile Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Val
 195 200 205
 Ile Cys Ile Ala Ser Leu Ile Ser Pro Tyr Arg Lys Pro Pro Asp Ala
 210 215 220
 Cys Arg Ser Leu Leu Pro Glu Gly Asp Phe Ile Glu Val Phe Met Asp
 225 230 235 240
 Val Pro Leu Lys Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys
 245 250 255
 Leu Ala Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro
 260 265 270
 Tyr Glu Pro Pro Leu Lys Ser Glu Ile Val Leu His Gln Lys Leu Gly
 275 280 285
 Met Cys Asp Ser Pro Cys Asp Leu Ala Asp Ile Val Ile Ser Tyr Leu
 290 295 300
 Glu Glu Asn Gly Tyr Leu Lys Ala
 305 310
 <210> 14
 <211> 276
 <212> PRT
 <213> Arabidopsis thaliana
 <400> 14
 Met Ile Ala Ala Gly Ala Lys Ser Leu Leu Gly Leu Ser Met Ala Ser
 1 5 10 15
 Pro Lys Gly Ile Phe Asp Ser Asn Ser Met Ser Asn Ser Arg Ser Val
 20 25 30
 Val Val Val Arg Ala Cys Val Ser Met Asp Gly Ser Gln Thr Leu Ser
 35 40 45
 His Asn Lys Asn Gly Ser Ile Pro Glu Val Lys Ser Ile Asn Gly His
 50 55 60
 Thr Gly Gln Lys Gln Gly Pro Leu Ser Thr Val Gly Asn Ser Thr Asn
 65 70 75 80
 Ile Lys Trp His Glu Cys Ser Val Glu Lys Val Asp Arg Gln Arg Leu
 85 90 95

Leu Asp Gln Lys Gly Cys Val Ile Trp Val Thr Gly Leu Ser Gly Ser
 100 105 110
 Gly Lys Ser Thr Leu Ala Cys Ala Leu Asn Gln Met Leu Tyr Gln Lys
 115 120 125
 Gly Lys Leu Cys Tyr Ile Leu Asp Gly Asp Asn Val Arg His Gly Leu
 130 135 140
 Asn Arg Asp Leu Ser Phe Lys Ala Glu Asp Arg Ala Glu Asn Ile Arg
 145 150 155 160
 Arg Val Gly Glu Val Ala Lys Leu Phe Ala Asp Ala Gly Ile Ile Cys
 165 170 175
 Ile Ala Ser Leu Ile Ser Pro Tyr Arg Thr Asp Arg Asp Ala Cys Arg
 180 185 190
 Ser Leu Leu Pro Glu Gly Asp Phe Val Glu Val Phe Met Asp Val Pro
 195 200 205
 Leu Ser Val Cys Glu Ala Arg Asp Pro Lys Gly Leu Tyr Lys Leu Ala
 210 215 220
 Arg Ala Gly Lys Ile Lys Gly Phe Thr Gly Ile Asp Asp Pro Tyr Glu
 225 230 235 240
 Pro Pro Leu Asn Cys Glu Ile Ser Leu Gly Arg Glu Gly Gly Thr Ser
 245 250 255
 Pro Ile Glu Met Ala Glu Lys Val Val Gly Tyr Leu Asp Asn Lys Gly
 260 265 270
 Tyr Leu Gln Ala
 275

GENERAL POWER OF ATTORNEY
(Concerning Several International Patent Applications)

The undersigned, Vernon R. Rice, Vice President and Assistant General Counsel of E. I. DU PONT DE NEMOURS AND COMPANY, 1007 Market Street, Wilmington, Delaware 19898 USA ("DuPont"), hereby confirms that the power to sign for DuPont has been granted to various individuals (as set forth in the attached excerpt from DuPont's Patent Board Rules of Procedure (January 1988), Appendix Section III.A.4), including the Chairman, Vice-Chairman, and those individuals who are Assistant Secretaries of the Patent Board. Currently these Assistant Secretaries are:

Roger A. Bowman
Linda J. Davis
John E. Griffiths

Miriam D. Meconnahey
Dorothy W. Shafer
Deborah A. Meginniss

In addition, the authority to act on behalf of DuPont before the competent International Authorities in connection with any and all international patent applications filed by it with the United States as Receiving Office and to make or receive payments on its behalf is hereby granted to:

Beardell, Lori Y.	<u>34,293</u>	Katz, Elliott A.	<u>26,396</u>
Belopolsky, Irma	<u>43,319</u>	Kelly, Patricia L.	<u>39,247</u>
Benjamin, Steven C.	<u>36,087</u>	King, Karen K.	<u>34,850</u>
Birch, Linda D.	<u>38,719</u>	Kuller, Mark D.	<u>31,925</u>
Bowen, Jr., Alanson G.	<u>24,027</u>	Kruckiel, Charles E.	<u>27,344</u>
Christenbury, Lynne M.	<u>30,971</u>	Jarnholm, Arne R.	<u>30,396</u>
Cotreau, William J.	<u>36,490</u>	Langworthy, John A.	<u>32,255</u>
Deitch, Gerald E.	<u>30,457</u>	Lerman, Bart E.	<u>31,897</u>
Deshmukh, Sudhir	<u>33,677</u>	Levitt, Cary A.	<u>31,848</u>
Dobson, Kevin S.	<u>40,296</u>	Magee, Thomas H.	<u>27,355</u>
Duffy, Roseanne R.	<u>33,869</u>	Mayer, Nancy S.	<u>29,190</u>
Edwards, Mark A.	<u>39,542</u>	Medwick, George M.	<u>27,456</u>
Estrin, Barry	<u>26,452</u>	Morrissey, Bruce W.	<u>30,663</u>
Evans, Craig H.	<u>31,825</u>	Santopietro, Lois A.	<u>36,264</u>
Fair, Tamera L.	<u>35,867</u>	Schaeffer, Andrew L.	<u>33,605</u>
Feltham, S. Neil	<u>36,506</u>	Sebree, Chyrea J.	<u>45,348</u>
Floyd, Linda Axamethy	<u>33,692</u>	Shafer, Robert J.	<u>24,437</u>
Frank, George A.	<u>27,636</u>	Shay, Lucas K.	<u>34,724</u>
Golian, Andrew G.	<u>25,293</u>	Shipley, James E.	<u>32,003</u>
Gorman, Thomas W.	<u>31,959</u>	Siegeil, Barbara C.	<u>30,684</u>
Gould, David J.	<u>25,338</u>	Sinnott, Jessica M.	<u>34,015</u>
Griffiths, John E.	<u>32,647</u>	Steinberg, Thomas W.	<u>37,013</u>
Hamby, Jane O.	<u>32,872</u>	Stevenson, Robert B.	<u>26,039</u>
Hamby, William H.	<u>31,521</u>	Strickland, Frederick D.	<u>39,041</u>
Heiser, David E.	<u>31,366</u>	Tessari, Joseph A.	<u>32,177</u>
Hendrickson, John S.	<u>30,847</u>	Tulloch, Rebecca W.	<u>36,297</u>
Jones, Brian C.	<u>37,857</u>	Walker, P. Michael	<u>32,602</u>
Joung, J. Kenneth	<u>41,881</u>	Wang, Chen	<u>38,650</u>

The undersigned ratifies fully all actions already taken by the above-named individuals in accordance with the authority granted hereby.

E. I. DU PONT DE NEMOURS AND COMPANY

By: _____

Vernon R. Rice

Vice President and Assistant General Counsel

Date: _____

5/1/2000

DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

GENES ENCODING SULFATE ASSIMILATION PROTEINS

the specification of which is attached hereto unless the following box is checked:

☒ was filed on **13 JULY 1999** as U.S. Application No. _____ or PCT International Application No.**PCT/US99/15809** and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.

Country

Filing Date

Priority Claimed (Yes/No)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.

U.S. Filing Date

60/092,833

14 JULY 1998

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.

Filing Date

Status (patented, pending or abandoned)

POWER OF ATTORNEY: I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:Name: **WILLIAM R. MAJARIAN**Registration No.: **41,173**

Send correspondence and direct telephone calls to:

WILLIAM R. MAJARIAN**E. I. du Pont de Nemours and Company
Legal - Patents
Wilmington, DE 19898, U.S.A.**Tel. No.
(302) 992-4926Fax No.
(302) 892-7949

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INVENTOR(S)

Full Name of Inventor	Last Name FALCO	First Name SAVERIO	Middle Name CARL
	Signature (please sign full name): <i>[Signature]</i>		Date: 9/1/99
Residence & Citizenship	City ARDEN	State or Foreign Country DELAWARE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 1902 MILLERS ROAD	City ARDEN	State or Country DELAWARE
			Zip Code 19810
Full Name of Inventor	Last Name ALLEN	First Name STEPHEN	Middle Name M.
	Signature (please sign full name): <i>[Signature]</i>		Date: 9/2/99
Residence & Citizenship	City WILMINGTON	State or Foreign Country DELAWARE	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 2225 ROSEWOOD DRIVE	City WILMINGTON	State or Country DELAWARE
			Zip Code 19810
Full Name of Inventor	Last Name ANDERSON	First Name SHAWN	Middle Name L.
	Signature (please sign full name): <i>[Signature]</i>		Date: 9/7/99
Residence & Citizenship	City WEST GROVE	State or Foreign Country PENNSYLVANIA	Country of Citizenship U.S.A.
Post Office Address	Post Office Address 3 BOOR'S COVE LANE	City WEST GROVE	State or Country PENNSYLVANIA
			Zip Code 19390

☐ Additional Inventors are being named on separately numbered sheets attached hereto.